Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:ADMA

ADMA Biologics Q3 2026 Earnings Date & Estimates

ADMA Biologics logo
$10.32 -0.01 (-0.05%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ADMA Biologics is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ADMA Biologics in Q3 2026

ADMA Biologics is expected to post earnings of $0.19 per share on revenue of $138.12 million. In the same quarter a year earlier ADMA Biologics reported $0.16 per share on revenue of $134.22 million. ADMA Biologics last reported on August 5, 2026, posting $0.16 per share and missing the $0.1633 consensus estimate. ADMA Biologics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.19
Expected Revenue
$138.12 million
Prior-Year EPS
$0.16
Prior-Year Revenue
$134.22 million
Expected EPS Growth
+18.8%
Expected Revenue Growth
+2.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.16 (Missed by -$0.0033)
Last Quarter Revenue
$124.40 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

ADMA Biologics Q3 2026 Earnings FAQ

ADMA Biologics (NASDAQ:ADMA) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

ADMA Biologics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ADMA Biologics to post earnings of $0.19 per share for Q3 2026.

The consensus revenue estimate for ADMA Biologics is $138.12 million for Q3 2026.

ADMA Biologics Earnings Headlines

ADMA Biologics Inc (NASDAQ:ADMA) Stock Has Consensus Target Price of $18.67 According to Analysts
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085979
Contrasting ADMA Biologics (NASDAQ:ADMA) & PTC Therapeutics (NASDAQ:PTCT)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068356
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
October 9 at 1:00 AM  |  Profits Run (Ad)
ADMA Biologics (ADMA), Why Is It Back In The Spotlight?
September 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/adma-biologics-adma-why-back-130654966.html
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
September 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/berger-montague-pc-investigates-adma-biologics-incs-board-of-directors-for-breach-of-fiduciary-duty-nasdaq-adma-302870867.html
ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade)
September 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942290-adma-biologics-stock-maybe-bears-right-rating-downgrade
See More ADMA Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ADMA Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADMA Biologics and other key companies, straight to your email.

About ADMA Biologics

ADMA Biologics (NASDAQ:ADMA), Inc. is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company’s operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products.

ADMA’s commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases. The company also markets Nabi-HB, a hepatitis B immune globulin used to help prevent hepatitis B infection in certain clinical situations.

Headquartered in Boca Raton, Florida, ADMA serves the U.S. specialty pharmaceutical and healthcare markets through its plasma collection, manufacturing and commercial operations. The company was founded in 2004 and is led by President and Chief Executive Officer Adam S. Grossman.

View ADMA Biologics Profile
Earnings Tools